Clinical Trials Hold – BiotechReality – Information Intelligence System for Biopharma

Gilead Sciences, Inc. has updated on the clinical program for two experimental HIV-1 medicines: GS-1720, a new nucleoside reverse transcriptase translocation inhibitor (NRTTI), and GS-4182, a potent capsid inhibitor. These compounds are being tested as part of a multi-pronged approach to develop long-acting HIV medicines. In accordance with Gilead, though these drugs have been found to possess antiviral activity in phase-1 trials, the Phase 1b trials currently ongoing have brought to light tolerability issues such as injection-site reactions and elevated liver enzymes among some of the participants. Therefore, the company has suspended dosing in these trials to enable an intensive review of the safety data coming in.GS-1720 and GS-4182 were being investigated as potential long-acting injectable regimens to reduce the burden of once-daily medication for HIV patients, both in combination and as monotherapy. The plan aligns with Gilead's long-term commitment to HIV treatment innovation and its pipeline initiatives towards sustainable, efficient regimens. Gilead emphasized that trial participants are continuously monitored and that no significant side effects have been directly linked to the investigational medications. The company is carrying out more evaluations and will make a decision regarding the products' future development after consulting with independent specialists and regulatory officials. The statement demonstrates the open communication of Gilead with the scientific community and impacted stakeholders, and the company reiterates its commitment to creating transformative medicines for individuals with HIV. Source: Gilead Sciences Last Modified:

Tag: Clinical Trials Hold

Gilead Provides Clinical Update on Investigational HIV-1 Treatments GS-1720 and GS-4182

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment